TICKERNERD
Menu
IVVDIVVDHealthcare · Biotechnology

IVVD Stock Forecast: Invivyd, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$0.72
+5.09% on the day

The 3 Wall Street analysts covering Invivyd, Inc. hold a median 12-month price target of $10 — +1287.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$212.4M
Ticker Nerd rank
19 / 100
Median analyst target
$10
Analysts covering
3
Total return, dividends reinvested
1W
−2.6%
1M
−10.0%
YTD
−70.8%
1Y
−9.8%
From 52W high
−75.0%
From 52W low
+38.6%
$0.52
$2.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IVVD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Invivyd, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
68
Quality
61
Growth
52
Momentum
41
Value
36
Revisions
26
Accruals
18
Volatility
13
Issuance
12

Size (68): Smaller than most of the companies we track.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IVVD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IVVD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26IVVDHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +1287.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 July 2026BTIGReiteratesBuy$10
15 June 2026HC Wainwright & Co.ReiteratesBuy—
9 June 2026BTIGReiteratesBuy—
1 June 2026BTIGReiteratesBuy—
18 May 2026BTIGReiteratesBuy—
26 Feb 2026BTIGReiteratesBuy—
23 Dec 2025BTIGReiteratesBuy—
22 Dec 2025BTIGInitiatesBuy—
25 Nov 2025D. Boral CapitalDowngradeHold—
3 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
6 Oct 2025Cantor FitzgeraldInitiatesOverweight—
6 Oct 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 Aug 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
26 June 2025D. Boral CapitalMaintainsBuy—
26 June 2025HC Wainwright & Co.ReiteratesBuy—
28 May 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IVVD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IVVD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Invivyd, Inc. (IVVD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.4×

Cheaper than 86% of US stocks

Price / sales
3.6×

Cheaper than 36% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
−0.5×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
21.2%

Higher than 71% of US stocks

Earnings growth (YoY)
21.6%

Higher than 60% of US stocks

Gross margin
92.5%

Higher than 97% of US stocks

Operating margin
−320.8%

Higher than 9% of US stocks

Net margin
−183.9%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−95.9%

Higher than 13% of US stocks

Return on assets
−45.7%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IVVD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IVVDInvivyd, Inc.$212.4M
19
NERVMinerva Neurosciences, Inc.$213.4M
31
ALECAlector, Inc.$213.9M
41
YDESYD Bio Ltd.$210.2M
53
ANTXAN2 Therapeutics, Inc.$215.3M
74
TNXPTonix Pharmaceuticals Holding Corp.$218.0M
21
IMUXImmunic, Inc.$218.8M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Invivyd, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IVVD news & analysis

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

Invivyd reported a Q2 loss of $0.14 per share, slightly better than the Zacks Consensus Estimate of a $0.15 loss but wider than the $0.12 per-share loss from a year earlier. The results lagged revenue estimates.

Why it matters — An IVVD watcher would care because the company's quarterly results missed revenue expectations and showed a larger year-over-year loss, indicating financial performance continued to weaken.

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 13 Aug 2026neutral

Invivyd, Inc. reported its financial results for the second quarter ended June 30, 2026, along with recent business highlights, in an August 13 announcement.

Why it matters — Quarterly financial results and business updates provide a periodic snapshot of the company's performance and operational progress.

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Aug 2026neutral

On August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of 277,500 shares of its common stock as a material inducement for their employment, under Nasdaq Listing Rule 5635(c)(4) and the company's 2026 Inducement Plan. The grant was announced on August 4, 2026.

Why it matters — The option grant signals new hires and potential equity dilution for existing shareholders, and reflects inducement compensation practices a IVVD watcher would monitor.

FAQ

Frequently asked questions about IVVD stock

What is the IVVD stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Invivyd, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IVVD stock a buy right now?

Of the 3 analysts covering Invivyd, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Invivyd, Inc. 19 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IVVD?

As at 15 Aug 2026, Invivyd, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (68 of 100).

Will IVVD stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1287.2% from the last close, and Ticker Nerd's factor model ranks Invivyd, Inc. 19 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IVVD stock forecast for 2030?

No analyst covering Invivyd, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IVVD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has IVVD stock performed over the past year?

Invivyd, Inc. returned -9.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Invivyd, Inc. do?

Invivyd Inc. is a biopharmaceutical company dedicated to delivering protection from serious viral infectious diseases through innovative antibody-based therapies.

What is the latest news on IVVD?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates". Invivyd reported a Q2 loss of $0.14 per share, slightly better than the Zacks Consensus Estimate of a $0.15 loss but wider than the $0.12 per-share loss from a year earlier. The results lagged revenue estimates.

Company

About Invivyd, Inc.

Invivyd Inc. is a biopharmaceutical company dedicated to delivering protection from serious viral infectious diseases through innovative antibody-based therapies. It employs a proprietary integrated technology platform that combines state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering to develop potent monoclonal antibodies more resistant to virus evolution than the natural human immune system. The company focuses on a robust pipeline of product candidates for prevention and treatment of high-need indications, starting with COVID-19—such as pemivibart, an extended-half-life monoclonal antibody authorized for pre-exposure prophylaxis—and expanding into influenza and other viral threats. Invivyd Inc. supports patients through programs offering benefits investigations, access and reimbursement assistance, treatment coordination, and payor advocacy. It also pursues research and development collaborations with academic institutions, medical centers, and biopharma partners to advance antibody discovery and engineering. With expertise in monoclonal antibody development, clinical trial management, and regulatory affairs for biologics, Invivyd Inc. aims to protect vulnerable populations from evolving viral threats. Headquartered in Waltham, Massachusetts, the company operates from facilities in New Haven, Connecticut.

CEO Ms. Heidi Spurling M.S. · 122 employees · United States · https://www.invivyd.com